Insider · CIK 0001741382

Beetham Thomas W.

Reports to the SEC for 3 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001741382

Forms 4 and 5

Insider transactions

44 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-03	VRDNViridian Therapeutics, Inc.\DE · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−9,409 sh	—	—	28,227
2026-03-03	VRDNViridian Therapeutics, Inc.\DEF Tax Payment	Chief Operating Officer	FTax Payment	−3,048 sh	$30.19	−$92K	13,361
2026-03-03	VRDNViridian Therapeutics, Inc.\DEM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+9,409 sh	—	—	16,409
2026-03-03	VRDNViridian Therapeutics, Inc.\DEF Tax Payment	Chief Operating Officer	FTax Payment	−3,138 sh	$29.32	−$92K	13,271
2026-03-02	VRDNViridian Therapeutics, Inc.\DE · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+177K sh	—	—	176,550
2026-03-02	VRDNViridian Therapeutics, Inc.\DE · Restricted Stock UnitsA Award	Chief Operating Officer	AAward	+35.3K sh	—	—	35,300
2025-03-03	VRDNViridian Therapeutics, Inc.\DE · Restricted Stock UnitsA Award	Chief Operating Officer	AAward	+37.6K sh	—	—	37,636
2025-03-03	VRDNViridian Therapeutics, Inc.\DE · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+226K sh	—	—	225,814
2024-09-27	VRDNViridian Therapeutics, Inc.\DEP Purchase	Chief Operating Officer	PPurchase	+5,000 sh	$23.41	+$117K	6,000
2023-10-30	VRDNViridian Therapeutics, Inc.\DE · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+474K sh	—	—	474,400
2022-11-30	DNTHDianthus Therapeutics, Inc. /DE/A Award	See Remarks	AAward	+3,000 sh	$0.94	+$2,820	19,897
2022-08-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	See Remarks	AAward	+75K sh	—	—	75,000
2022-05-31	DNTHDianthus Therapeutics, Inc. /DE/A Award	See Remarks	AAward	+3,000 sh	$0.99	+$2,970	16,897
2022-05-17	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	See Remarks	AAward	+50K sh	—	—	50,000
2022-02-15	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	See Remarks	AAward	+75K sh	—	—	75,000
2021-09-16	DNTHDianthus Therapeutics, Inc. /DE/S Sale	See Remarks	SSale	−6,103 sh	$6.73	−$41.1K	13,897
2021-09-14	DNTHDianthus Therapeutics, Inc. /DE/A Award	See Remarks	AAward	+20K sh	—	—	20,000
2021-06-14	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	See Remarks	AAward	+200K sh	—	—	200,000
2021-03-20	KNSAKiniksa Pharmaceuticals International, plc · Restricted Share UnitsA Award	EVP & Chief Legal Officer	AAward	+4,287 sh	—	—	4,287
2021-03-20	KNSAKiniksa Pharmaceuticals International, plc · Restricted Share UnitsA Award	EVP & Chief Legal Officer	AAward	+5,855 sh	—	—	5,855
2021-03-16	KNSAKiniksa Pharmaceuticals International, plc · Restricted Share UnitsA Award	EVP & Chief Legal Officer	AAward	+8,769 sh	—	—	8,769
2021-03-16	KNSAKiniksa Pharmaceuticals International, plc · Share OptionA Award	EVP & Chief Legal Officer	AAward	+52.6K sh	—	—	52,611
2021-02-03	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−2,477 sh	$22.09	−$54.7K	297,523
2021-02-03	KNSAKiniksa Pharmaceuticals International, plc · Class B Common SharesC Conversion	EVP & Chief Legal Officer	CConversion	−300K sh	—	—	114,157
2021-02-03	KNSAKiniksa Pharmaceuticals International, plcC Conversion	EVP & Chief Legal Officer	CConversion	+300K sh	—	—	300,000
2020-09-10	KNSAKiniksa Pharmaceuticals International, plc · Share OptionA Award	EVP & Chief Legal Officer	AAward	+75K sh	—	—	75,000
2020-07-01	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−26.7K sh	$25.32	−$677K	2,855
2020-07-01	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−2,855 sh	$25.84	−$73.8K	0
2020-06-10	KNSAKiniksa Pharmaceuticals International, plc · Share OptionM Exercise/Conversion	EVP & Chief Legal Officer	MExercise/Conversion	−13.8K sh	—	—	112,189
2020-06-10	KNSAKiniksa Pharmaceuticals International, plcM Exercise/Conversion	EVP & Chief Legal Officer	MExercise/Conversion	+13.8K sh	$1.59	+$21.9K	43,341
2020-06-10	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−13.8K sh	$25.07	−$345K	29,589
2020-04-21	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−1,563 sh	$19.56	−$30.6K	30,544
2020-04-21	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−955 sh	$20.44	−$19.5K	29,589
2020-04-20	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−47.4K sh	$19.06	−$904K	32,107
2020-03-13	KNSAKiniksa Pharmaceuticals International, plc · Share OptionA Award	EVP & Chief Legal Officer	AAward	+75K sh	—	—	75,000
2020-02-14	KNSAKiniksa Pharmaceuticals International, plcS Sale	EVP & Chief Legal Officer	SSale	−59 sh	$18.58	−$1,096.22	79,530
2019-09-17	KNSAKiniksa Pharmaceuticals International, plc · Share OptionA Award	EVP & Chief Legal Officer	AAward	+45K sh	—	—	45,000
2019-03-04	KNSAKiniksa Pharmaceuticals International, plc · Share OptionA Award	EVP & Chief Legal Officer	AAward	+42K sh	—	—	42,000
2018-09-20	KNSAKiniksa Pharmaceuticals International, plc · Share OptionA Award	EVP & Chief Legal Officer	AAward	+45K sh	—	—	45,000
2018-05-29	KNSAKiniksa Pharmaceuticals International, plc · Series A Preferred SharesC Conversion	EVP & Chief Legal Officer	CConversion	−48.2K sh	—	—	0
2018-05-29	KNSAKiniksa Pharmaceuticals International, plcC Conversion	EVP & Chief Legal Officer	CConversion	+6,392 sh	—	—	79,589
2018-05-29	KNSAKiniksa Pharmaceuticals International, plc · Class B Common SharesC Conversion	EVP & Chief Legal Officer	CConversion	+48.2K sh	—	—	414,157
2018-05-29	KNSAKiniksa Pharmaceuticals International, plc · Series C Preferred SharesC Conversion	EVP & Chief Legal Officer	CConversion	−6,392 sh	—	—	0
2018-02-09	KNSAKiniksa Pharmaceuticals International, plc · Series C Preferred SharesP Purchase	EVP & Chief Legal Officer	PPurchase	+6,392 sh	$15.64	+$100K	6,392

Recent filings

Accepted (ET)
Mar 94/A
Beetham Thomas W.0001193125-26-099014
SEC(opens sec.gov)
Mar 44
Beetham Thomas W.0001193125-26-092040
SEC(opens sec.gov)
Mar 44
Beetham Thomas W.0000950170-25-032887
SEC(opens sec.gov)
Sep 304
Beetham Thomas W.0000950170-24-110485
SEC(opens sec.gov)
Nov 14
Beetham Thomas W.0000950170-23-057520
SEC(opens sec.gov)
Dec 24
Beetham Thomas W.0000899243-22-037435
SEC(opens sec.gov)
Aug 14
Beetham Thomas W.0000899243-22-027273
SEC(opens sec.gov)
Jun 64
Beetham Thomas W.0000899243-22-021182
SEC(opens sec.gov)
May 194
Beetham Thomas W.0000899243-22-018801
SEC(opens sec.gov)
Feb 174
Beetham Thomas W.0000899243-22-006813
SEC(opens sec.gov)
Sep 204
Beetham Thomas W.0000899243-21-036598
SEC(opens sec.gov)
Sep 164
Beetham Thomas W.0000899243-21-036332
SEC(opens sec.gov)
Jun 154
Beetham Thomas W.0000899243-21-023865
SEC(opens sec.gov)
Mar 234
Beetham Thomas W.0001179110-21-003728
SEC(opens sec.gov)

Companies

Address

C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 103A

WALTHAM, MA, 02453